Mucosal Melanoma of the Head and Neck: A 45-Year Experience of a Tertiary Cancer Center
Authors:
- Stefano CavalieriSCStefano Cavalieri
- Benedetta Lombardi StocchettiBSBenedetta Lombardi Stocchetti
- Andrea SpagnolettiASAndrea Spagnoletti
- Francesco BarrettaFBFrancesco Barretta
- Andrea AnichiniAAAndrea Anichini
- Patrizia BoracchiPBPatrizia Boracchi
- Gabrina TragniGTGabrina Tragni
- Lorenza Di GuardoLGLorenza Di Guardo
- Alice IndiniAIAlice Indini
- Barbara ValeriBVBarbara Valeri
- Roberto BianchiRBRoberto Bianchi
- Sarah ColomboSCSarah Colombo
Open Access
Abstract
Background/Objectives. Head and neck mucosal melanoma (HNMM) is a rare, aggressive malignancy with poor outcomes and limited evidence to guide prognostication and treatment. A detailed assessment of long-term survival and prognostic factors is needed to inform clinical management and staging. This work aimed to describe outcomes and prognostic factors in HNMM patients treated over 45 years. Methods. This was a retrospective observational cohort study of consecutive patients treated at a tertiary referral center in Italy from 1975 to 2020. Random-forest-based screening informed covariate selection for Cox models. Endpoints were overall survival (OS), disease-free survival (DFS), and post-recurrence DFS (prDFS). Associations with clinical and pathological variables were evaluated using Kaplan–Meier estimates, log-rank tests, and multivariable Cox regression. Results. Among 112 patients (median follow-up, 121.1 months), 3-/5-year OS was 42.8%/28.0%, DFS 20.5%/13.2%, and 1-/3-year prDFS 36.7%/10.9%. Ulceration was associated with worse OS (HR 2.12; 95% CI 1.05–4.26) and DFS (HR 2.23; 95% CI 1.16–4.28). Male sex showed a trend toward poorer OS and DFS. Regional lymph-node treatment correlated strongly with OS and prDFS (overall p < 0.001), with neck dissection indicating unfavorable risk (OS HR 5.22; 95% CI 2.39–11.40). Conclusions. HNMM remains a high-mortality disease with frequent recurrence. Ulceration and nodal involvement were key adverse prognostic factors, while surgery was associated with improved survival. The findings support incorporating ulceration into future staging and highlight the potential for durable control through salvage surgery. Further investigation of treatment intensification, biomarkers, and multimodal strategies is warranted.Keywords
Funding Information
- Italian Ministry of Health “Ricerca Corrente” funds
This publication has 52 references indexed in Scilit:
- Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysisClinical and Translational Medicine, 2025
- Mucosal Melanoma of the Oral Cavity: What is the Role of Elective Neck Dissection?The Laryngoscope, 2022
- Regional disease control in sinonasal mucosal melanoma: Systematic review and meta‐analysisHead & Neck, 2020
- Challenges in Computational Statistics and Data Mining2016
- Update on primary head and neck mucosal melanomaHead & Neck, 2014
- Mucosal Melanoma of the Head and NeckJAMA Otolaryngology–Head & Neck Surgery, 2011
- Postoperative Radiotherapy in Head and Neck Mucosal MelanomaJAMA Otolaryngology–Head & Neck Surgery, 2010
- The Role of Postoperative Adjuvant Radiation Therapy in the Treatment of Mucosal Melanomas of the Head and Neck RegionJAMA Otolaryngology–Head & Neck Surgery, 2003
- Primary mucosal malignant melanoma of the head and neckHead & Neck, 2002
- Malignant mucosal melanoma of the head and neckCancer, 1997